InvestorsHub Logo
Followers 52
Posts 4109
Boards Moderated 0
Alias Born 07/03/2005

Re: None

Thursday, 08/02/2018 7:06:38 AM

Thursday, August 02, 2018 7:06:38 AM

Post# of 14953
Looking Ahead At Catalysts – Sorrento Therapeutics (SRNE)
Aug. 1, 2018 8:01 PM ET|

Summary

After years of acquisitions, preclinical research and early JV’s, SRNE is now advancing multiple clinical programs (e.g. CAR-T therapies, advanced analgesics) and is set to enter its next growth phase.

With the clinical programs underway, CEO Henry Ji is focusing efforts on funding, with options that range from dual-listing on the SEHK in China to more substantial partnerships.

SRNE is primed for growth. It’s undervalued relative to its most conservative analyst price target of $10 and has notable upside on delivery of multiple catalysts in the next 3-9 months.

https://seekingalpha.com/instablog/47373598-c-capital-research/5194677-looking-ahead-catalysts-sorrento-therapeutics-srne

Opti

Hebrews 11:6 And without faith it is impossible to please Him, for he who comes to God must believe that He is and that He is a rewarder of those who seek Him.